Maxcyte (MXCT) Income from Continuing Operations (2020 - 2025)
Historic Income from Continuing Operations for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$12.4 million.
- Maxcyte's Income from Continuing Operations fell 743.27% to -$12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.6 million, marking a year-over-year decrease of 2768.92%. This contributed to the annual value of -$41.1 million for FY2024, which is 825.88% down from last year.
- Latest data reveals that Maxcyte reported Income from Continuing Operations of -$12.4 million as of Q3 2025, which was down 743.27% from -$12.4 million recorded in Q2 2025.
- Maxcyte's Income from Continuing Operations' 5-year high stood at -$2.7 million during Q3 2021, with a 5-year trough of -$12.4 million in Q3 2025.
- For the 5-year period, Maxcyte's Income from Continuing Operations averaged around -$8.2 million, with its median value being -$9.4 million (2024).
- Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 4275.92% in 2022, then tumbled by 16754.85% in 2023.
- Quarter analysis of 5 years shows Maxcyte's Income from Continuing Operations stood at -$4.9 million in 2021, then increased by 1.33% to -$4.8 million in 2022, then dropped by 9.74% to -$5.3 million in 2023, then crashed by 100.78% to -$10.6 million in 2024, then fell by 17.17% to -$12.4 million in 2025.
- Its Income from Continuing Operations was -$12.4 million in Q3 2025, compared to -$12.4 million in Q2 2025 and -$10.3 million in Q1 2025.